Compare ARK Genomic Revolution ETF (ARKG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Zimmer Biomet Holdings Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Zimmer Biomet Holdings Inc trades at $91.8 (market cap $17.67B). The key difference: Zimmer Biomet Holdings Inc pays a 1.05% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $107.71 |
52-Week Low | $23.09 | $79.58 |
Market Cap | — | $17.67B |
Enterprise Value | — | $24.72B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Zimmer Biomet (ZBH) trades at $91.34, up 2.36% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong profitability with a 70.03% gross margin and has beaten earnings estimates for three consecutive quarters. Recent developments include a $140M acquisition and plans to hire 500 employees in India, signaling growth initiatives.
Outlook is cautiously optimistic with a consensus price target of $98.00, though rising debt levels and competitive pressures pose risks. The stock offers steady dividend income and share repurchases, but investors should weigh execution risks against solid cash flow generation and market positioning in medical devices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
